Analysts See $0.01 EPS for IntelliPharmaCeutics Intl Inc (USA) (IPCI)

September 17, 2017 - By Henry Gaston

 Analysts See $0.01 EPS for IntelliPharmaCeutics Intl Inc (USA) (IPCI)

Analysts expect IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report $0.01 EPS on October, 12.They anticipate $0.08 EPS change or 114.29 % from last quarter’s $-0.07 EPS. IPCI’s profit would be $312,383 giving it 24.03 P/E if the $0.01 EPS is correct. After having $-0.06 EPS previously, IntelliPharmaCeutics Intl Inc (USA)’s analysts see -116.67 % EPS growth. The stock decreased 3.95% or $0.039 on September 15, reaching $0.961. About 214,950 shares traded. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 16.57% since September 17, 2016 and is uptrending. It has underperformed by 0.13% the S&P500.

Intellipharmaceutics International Inc is a Canada pharmaceutical firm engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has market cap of $30.02 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular.

More notable recent IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) news were published by: Globenewswire.com which released: “Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported …” on July 31, 2017, also Seekingalpha.com with their article: “IntelliPharmaCeutics International – Very Low Downside And Huge Upside” published on July 25, 2017, Marketwatch.com published: “0.9767” on November 12, 2010. More interesting news about IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) were released by: Globenewswire.com and their article: “Intellipharmaceutics Provides Operational Update” published on September 05, 2017 as well as Globenewswire.com‘s news article titled: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” with publication date: April 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.